Kalender
Berita
Pasar
Komoditas
Indeks
Saham
Mata Uang
Kripto
Obligasi
Indikator
Negara-negara
Prakiraan
Komoditas
Indeks
Mata Uang
Kripto
Obligasi
Negara-negara
Indikator
Kalender
Berita
Pasar
Komoditas
Indeks
Saham
Mata Uang
Kripto
Obligasi
Pendapatan
Liburan
Negara-negara
Amerika Serikat
Inggris Raya
Kawasan Euro
Australia
Kanada
Jepang
Tiongkok
Brazil
Rusia
India
Selanjutnya Negara-negara
Indikator
Suku Bunga
Tingkat Inflasi
Tingkat Pengangguran
Pertumbuhan PDB (q-to-q)
Pdb Per Kapita
Transaksi Berjalan
Cadangan Emas
Utang Pemerintah
Produksi Minyak Mentah
Harga Bensin
Peringkat Kredit
Selanjutnya Indikator
Prakiraan
Komoditas
Indeks
Mata Uang
Kripto
Obligasi
Negara-negara
Indikator
Apps
App Store
Google Play
Twitter
Akebia Therapeutics | AKBA - Modal Saham Biasa
Keuangan
Harga Saham
USD
Aktiva
USD 362.52M
Kas Dan Setara
USD 162.64M
Biaya Penjualan
USD 10.34M
Aset Lancar
USD 243.48M
Kewajiban Lancar
USD 173.88M
UTANG
USD 46.51M
Dividen - Hasil
0
EBIT
USD -5.45M
EBITDA
USD 14.03M
Karyawan
167
Eps Laba Per Saham
USD -0.04
Modal Dan Cadangan
USD 27.38M
Laba Kotor Pada Penjualan
USD 47.28M
Beban Bunga Utang
362.52M
Modal Pinjaman
USD 36.4M
Kapitalisasi Pasar
USD 259.6M
Batas Pemasukan
USD -12.24M
Biaya Operasional
USD 63.08M
Laba Operasional
USD -5.45M
Modal Saham Biasa
USD 265.43M
Pe Harga Untuk Laba
1.63K
Laba Sebelum Pajak
USD -11.24M
Pendapatan Penjualan
USD 57.62M
Beban Penjualan Dan Administrasi
USD 23.53M
Saham
USD 13M
Kreditur Perdagangan
USD 8.39M
Debitur Perdagangan
USD 47.03M
Modal Saham Biasa
Perubahan
Tanggal
Acadia Pharmaceuticals
USD 169.18M
470K
2025-12
Agios Pharmaceuticals
USD 59.34M
892K
2026-03
Akebia Therapeutics
USD 265.42M
199K
2025-12
Alnylam Pharmaceuticals
USD 133.44M
1.07M
2026-03
Amgen
USD 540M
1000K
2026-03
Ardelyx
USD 246.97M
2.62M
2026-03
Astellas Pharma
JPY 1.79B
81K
2026-03
AstraZeneca
USD 1.55B
73K
2026-03
Bayer
EUR 982.42M
0
2025-12
BioMarin Pharmaceutical
USD 193.27M
969K
2026-03
Celltrion
KRW 218.61M
162.21K
2025-12
Cspc Pharmaceutical
CNY 11.52B
3.7M
2025-12
Deva Holding AS
TRY 200.02M
0
2023-09
Dianthus Therapeutics
USD 54.58M
11.36M
2026-03
Exelixis
USD 253.7M
8.78M
2026-03
Fresenius Medical Care
EUR 270.09M
9.2M
2026-03
GlaxoSmithKline
GBP 4.05B
20.6M
2026-03
Ionis Pharmaceuticals
USD 165.9M
3.93M
2026-03
Ironwood Pharmaceuticals
USD 160K
0
2024-12
J&J
USD 2.41B
1.74M
2025-12
Kangmei Pharma
CNY 13.83B
0
2026-03
Karyopharm Therapeutics
USD 18.31M
18.3M
2025-12
Knight Therapeutics
CAD 99.68M
24.66K
2025-09
Laboratorios Farma
EUR 51.82M
1.55M
2023-12
Lexicon Pharmaceuticals
USD 363.47M
67K
2025-12
Malin Corporation
EUR 200K
0
2024-12
Medical Developments International
AUD 112.66M
2.35M
2025-12
Moderna
USD 391M
2M
2025-09
Nektar Therapeutics
USD 20.38M
20.36M
2025-12
Neuren Pharmaceuticals
AUD 126.64M
38.63M
2025-12
Organigram Holdings
CAD 136.47M
1.34M
2026-03
Ovoca Bio
EUR 29.49M
18.43M
2025-06
Pharma Mar
EUR 17.36M
0
2026-03
Prothena
USD 53.08M
756K
2026-03
PTC Therapeutics
USD 81.47M
1.54M
2025-12
Qiagen NV
USD 216.56M
284.67K
2025-12
Regeneron Pharmaceuticals
USD 105M
300K
2026-03
Roche Holding
CHF 795.62M
699.54K
2025-12
Sanofi
EUR 1.21B
8.25M
2026-03
Sarepta Therapeutics
USD 105.57M
607K
2026-03
Sartorius
EUR 69.05M
0
2026-03
Sino Biopharmaceutical
CNY 17.89B
30.5M
2025-06
Tectonic Therapeutic
USD 18.83M
92.19K
2026-03
Tilray
USD 116.52M
5.01M
2025-09
Vanda Pharmaceuticals
USD 58K
0
2024-12
Zealand Pharma A/S
70.61M
319.68K
2025-12
Zz Pientze Pharmaceu
CNY 603.32M
0
2026-03
×